CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.1669, expectations were $-0.03. CytomX Therapeutics, Inc.
Cytomx Therapeutics Inc. (CTMX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 6,595,801 | $14,378,846 | 0.39% | |
| 2. | Tang Capital Management Kevin C. Tang | 6,450,000 | $14,061,000 | -2% | 1.46% |
| 3. | OrbiMed Advisors Samuel Isaly | 3,544,578 | $7,727,180 | 0.14% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 2,000,000 | $4,360,000 | 0% | |
| 5. | Sio Capital Michael Castor | 1,598,590 | $3,484,926 | 1.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.55 | 5,000 | 5,142 | 2023-03-29 | Filing | ||
| $10.33 | 9,000 | Officer | 9,979 | 2019-03-04 | Filing | |
| $12.00 | 3,000 | Officer | 3,000 | 2015-10-14 | Filing | |
| $12.00 | 5,000 | Officer | 5,000 | 2015-10-14 | Filing | |
| $12.00 | 5,000 | Director | 5,000 | 2015-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.09 | 5,268 | 117,728 | 2024-03-19 | Filing | ||
| $2.09 | 20,223 | 524,481 | 2024-03-19 | Filing | ||
| $2.09 | 2,971 | 85,686 | 2024-03-19 | Filing | ||
| $2.09 | 12,795 | 168,579 | 2024-03-19 | Filing | ||
| $2.09 | 6,562 | 110,060 | 2024-03-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,902,943 | $7,599,562 | 0% | |
| 2. | 1,136,135 | $1,761,009 | 0% | |
| 3. | 791,421 | $1,226,703 | 0% | |
| 4. | 702,654 | $1,089,359 | 0% | |
| 5. | 565,324 | $876,252 | 0% |
News See All
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only-mode.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2023 Financial Results. At this time, all participants are in a listen only-mode.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2023 Earnings Call Transcript
Operator: Good day, and welcome to the CytomX Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2023 Financial Results Call. Please be advised that today's call is being recorded.
5 Best Debt Free Penny Stocks to Invest In
In this article, we will be taking a look at the 5 best debt free penny stocks to invest in.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Biotech Stocks Under $10
In this article, we will take a look at the 10 best Biotech stocks under $10.
10 Small-Cap Stocks to Buy According to Billionaire Steve Cohen
In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen.
Is CTMX A Good Stock To Buy According To Hedge Funds?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their...